BiotechTube
Home/Puma Biotechnology/David T. Tarlowe
DT

David T. Tarlowe

Senior Vice President, General Counsel, and Corporate Secretary

Puma Biotechnology

Therapeutic Areas

OncologyBreast CancerLung Cancer

Puma Biotechnology Pipeline

DrugIndicationPhase
NERLYNX (neratinib, oral)Extended adjuvant treatment of HER2-positive early breast cancerApproved
Alisertib3rd-line+ Extensive-Stage Small Cell Lung Cancer (SCLC)Phase 3

Leadership Team at Puma Biotechnology

AH
Alan H. Auerbach
Chief Executive Officer, President, Founder, and Chairman
RJ
Robert J. Charnas
Chief Financial Officer
DD
Dr. David S. Hong
Senior Vice President, Clinical Development
DT
Dr. Timothy P. Clackson
Senior Vice President, Research and Development
View full Puma Biotechnology profile